Data Epilepsy Safety Sleep 
Veriheal
AUGUST 12, 2021
Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.
MMJ Recs
NOVEMBER 17, 2023
MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more. Seizure Control: For patients with epilepsy and seizure disorders, certain cannabis-based treatments have shown remarkable effectiveness in reducing the frequency and severity of seizures.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JUNE 15, 2021
The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,
Cannabis Law Report
DECEMBER 11, 2021
The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.
The Joint Blog
JANUARY 23, 2020
. “Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.”
Freedom Leaf
OCTOBER 15, 2018
On the basis of their review, the agency approved Epidiolex for use in treating rare forms of childhood epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S. will top $1.9 billion by 2022.
Cannabis Law Report
MAY 19, 2022
FDA states it has serious safety concerns with delta-8 THC. FDA considers delta-8 THC to pose serious health and safety risks. Many CBD users have reported improvements in: Stress; Anxiety; Sleep; Pain levels; Skin conditions including acne and eczema; Epilepsy”. In particular, FDA highlighted the following –.
Expert insights. Personalized for you.
58 
Let's personalize your content